MedTrace Logo

ABSORB Clinical Investigation, Cohort B

NCT00856856 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2019-02-07

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess the safety and performance of the BVS Everolimus Eluting Coronary Stent System (EECSS) in the treatment of patients with a maximum of two de novo native coronary artery lesions located in two different major epicardial vessels.

Currently in development at Abbott Vascular. Not available for sale in the United States.

Conditions

Interventions

DEVICE

Bioabsorbable Everolimus Eluting Coronary Stent

Bioabsorbable drug eluting stent implantation in the treatment of coronary artery disease

Sponsors & Collaborators

  • Abbott Medical Devices

    lead INDUSTRY

Principal Investigators

  • Patrick Serruys, MD · Erasmus Heart Center, Thorax Centrum

  • John Ormiston, MD · Auckland City Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2015-10-31
Completion
2016-03-31

Countries

  • Australia
  • Belgium
  • Denmark
  • France
  • Netherlands
  • New Zealand
  • Poland
  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00856856 on ClinicalTrials.gov